Literature DB >> 16166783

National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population.

Hiroshi Yoshizawa1, Junko Tanaka, Yuzo Miyakawa.   

Abstract

During the past 30 years, hepatocellular carcinoma (HCC) in Japan has kept linearly increasing from 10 to 30 per 100,000 population per year and is expected to grow further. The increment is attributed to infection with hepatitis C virus (HCV). Hence, there is a pressing need to find subjects with persistent HCV infection in the general population of Japan and take necessary measures to prevent HCC developing in them. As a first approach toward this goal, the sex- and age-specific prevalence of ongoing HCV infection was surveyed in 3,485,648 first-time blood donors during 1995-2000. Taking into account the size of subpopulations with different sex and age in Japan registered at the Census 2000, there are an estimated 884,954 HCV carriers aged from 16 to 69 years, and 759,316 (86%) of them are older than 40 years, with an increased risk for HCC; they are hidden in the society, without overt liver disease. The national 5-year project searching for HCV carriers in the general population was started in April 2002. Subjects are examinees of health check-ups, which they receive every 5 years when reaching the age of 40, as well as those at increased risk for HCV infection. The project detected HCV RNA in 14,672 of the 1,298,746 (1.1%) health check examinees and in 16,721 of the 624,734 (2.7%) high-risk individuals during the first fiscal year. Subjects found with HCV RNA have been referred to clinics and hospitals with expert hepatologists. Hopefully, this project will decrease HCC development in HCV carriers in Japan and be considered in other countries where increases in HCC are predicted from the current age-specific prevalence of anti-HCV. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 16166783     DOI: 10.1159/000087257

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  17 in total

1.  Current management of patients with hepatocellular carcinoma.

Authors:  Tatsuo Kanda; Sadahisa Ogasawara; Tetsuhiro Chiba; Yuki Haga; Masao Omata; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-07-28

Review 2.  Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Kiyoshi Hasegawa; Yasuhiko Sugawara; Wei Tang
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740

3.  Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients.

Authors:  Itaru Ozeki; Jun Akaike; Yoshiyasu Karino; Tomohiro Arakawa; Yasuaki Kuwata; Takumi Ohmura; Takahiro Sato; Naohiro Kamiya; Ichimaro Yamada; Kazuaki Chayama; Hiromitsu Kumada; Joji Toyota
Journal:  J Gastroenterol       Date:  2011-05-10       Impact factor: 7.527

4.  Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.

Authors:  Masao Omata; Laurentius A Lesmana; Ryosuke Tateishi; Pei-Jer Chen; Shi-Ming Lin; Haruhiko Yoshida; Masatoshi Kudo; Jeong Min Lee; Byung Ihn Choi; Ronnie T P Poon; Shuichiro Shiina; Ann Lii Cheng; Ji-Dong Jia; Shuntaro Obi; Kwang Hyub Han; Wasim Jafri; Pierce Chow; Seng Gee Lim; Yogesh K Chawla; Unggul Budihusodo; Rino A Gani; C Rinaldi Lesmana; Terawan Agus Putranto; Yun Fan Liaw; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2010-03-18       Impact factor: 6.047

5.  Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography.

Authors:  Ryota Masuzaki; Ryosuke Tateishi; Haruhiko Yoshida; Toru Arano; Koji Uchino; Kenichiro Enooku; Eriko Goto; Hayato Nakagawa; Yoshinari Asaoka; Yuji Kondo; Tadashi Goto; Hitoshi Ikeda; Shuichiro Shiina; Masao Omata; Kazuhiko Koike
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

6.  Pulmonary resection for non-small cell lung cancer in patients with hepatocellular carcinoma.

Authors:  Takashi Iwata; Noritoshi Nishiyama; Koshi Nagano; Nobuhiro Izumi; Shinjiro Mizuguchi; Ryuhei Morita; Takuma Tsukioka; Shoji Hanada; Kiyotoshi Inoue; Shoji Kubo; Shigekazu Takemura; Shigefumi Suehiro
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

7.  Hepatitis C: Should antiviral therapy be offered to elderly patients?

Authors:  Annarosa Floreani
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

8.  Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo.

Authors:  Hiroshi Abe; Kai Yoshizawa; Takuya Kitahara; Ryoichi Aizawa; Mika Matsuoka; Yoshio Aizawa
Journal:  J Gastroenterol       Date:  2008-12-24       Impact factor: 7.527

9.  Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.

Authors:  Hideki Fujii; Takeshi Nishimura; Atsushi Umemura; Taichiro Nishikawa; Kanji Yamaguchi; Michihisa Moriguchi; Yoshio Sumida; Hironori Mitsuyoshi; Chihiro Yokomizo; Saiyu Tanaka; Hiroki Ishikawa; Kenichi Nishioji; Hiroyuki Kimura; Shiro Takami; Yasuyuki Nagao; Takayuki Takeuchi; Toshihide Shima; Yoshihiko Sawa; Masahito Minami; Kohichiroh Yasui; Yoshito Itoh
Journal:  World J Hepatol       Date:  2015-12-08

10.  Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis.

Authors:  John F P Bridges; Liming Dong; Gisselle Gallego; Barri M Blauvelt; Susan M Joy; Timothy M Pawlik
Journal:  BMC Health Serv Res       Date:  2012-10-30       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.